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ABSTRACT: A great challenge toward Acquired Immunodeﬁciency
Syndrome (AIDS) treatment is to combat the HIV-1 virus. The major
problem of drug resistance has kept the virus one step ahead of the medical
community, and the call for more eﬀective drugs remains as urgent as ever.
Saquinavir, the ﬁrst inhibitor against HIV-1 protease, oﬀers the most
extensive clinical data regarding resistance mutations. In this work, we
examine L10I, G48V, L63P, A71V, G73S, V82A, and I84V single mutant
HIV-1 PR strains in complexes with saquinavir to elucidate drug−protease
interactions and dynamics. A comparative analysis of these mutations at the
molecular level may lead to a deeper understanding of saquinavir resistance.
The G48V mutation induces structural changes to the protease that reﬂect
upon the drug’s binding aﬃnity, as shown by MM−PBSA and
thermodynamic integration (TI) calculations (ΔΔGTI = 0.3 kcal/mol;
ΔΔGMM−PBSA = 1.2 kcal/mol). It was shown that mutations, which increase
the ﬂexibility of the ﬂaps (G48V, L63P, L10I) diminish binding. The preservation of hydrogen bonds of saquinavir with both the
active site and ﬂap residues in the wild-type and certain single mutants (A71V, V82A) is also crucial for eﬀective inhibition. It was
shown that mutations conferring major resistance (G48V, L63P, I84V) did not present these interactions. Finally, it was
indicated that a water-mediated hydrogen bond between saquinavir and Asp29 in the active site (wild-type, A71V, G73S)
facilitates a proper placement of the drug into the binding cavity that favors binding. Mutants lacking this interaction (G48V,
V82A, I84V) demonstrated reduced binding aﬃnities. This systematic and comparative study is a contribution to the elucidation
of the drug resistance mechanism in HIV-1 PR.
I. INTRODUCTION
The spread of acquired immunodeﬁciency syndrome (AIDS)
has proven a major clinical challenge as more than 33 million
people are infected worldwide.1 For the past three decades,
there has been extensive research of the human immunodeﬁ-
ciency virus (HIV) that has led to the discovery of several
antiviral agents. According to the U.S. FDA,2 currently there are
30 commercially available anti-HIV drugs, divided into 16
reverse transcriptase (RT) inhibitors, nine protease (PR)
inhibitors, one fusion inhibitor, one integrase inhibitor, one
entry inhibitor, and two combination drugs.3 Although most
treatment protocols had been relatively successful, the
therapeutic beneﬁts diminish over time due to the appearance
of drug resistance. This eventually led to the introduction of a
combinatorial regime involving RT and PR inhibitors, as
opposed to monodrug therapy. The administration of such
drug cocktails is called highly active antiretroviral therapy
(HAART)4 and has resulted in a great decrease in HIV
morbidity and mortality rates.5,6 Nevertheless, it became
apparent that the eﬀectiveness of HAART does not prevent
treatment failure. This is mainly due to problems in HAART
adherence and drug−drug interactions, while the emergence of
drug-resistant viral strains remains the most important
drawback.7,8
HIV-1 protease (HIV-1 PR) is an aspartic protease consisting
of two identical chains, with 99 amino acids each. The active
site of the protein comprises two aspartic acids (Asp) in
positions 25/25′ as parts of two catalytic triads (Asp−Thr−
Gly), common in most members of this family.9 The Asp−
Thr−Gly triplets are located at the bottom of a binding cleft,
which is covered by two ﬂaps (residues 44−55/44′−55′; Figure
1). The ﬂap region modulates the entrance of substrates to the
active site cavity.10,11 The ﬂaps have been also implicated in
direct interactions with substrates, thus anchoring them ﬁrmly
inside the binding cavity.12 Experimental and theoretical studies
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revealed that the ﬂaps in the apo form of HIV-1 PR are highly
ﬂexible and appear to be in equilibrium among three states,
namely “closed,” “open,” and “semi-open”;9,10,13 upon binding
of a substrate or inhibitor, it has been shown that they adopt
mainly a “closed” conformation.11,14
The emergence of drug resistant viral strains, in general,
presents the following pattern. An initial, single mutation leads
to the appearance of low level resistance, followed by the
accumulation of mutations in the protease that produces strains
with a high level of resistance against a speciﬁc inhibitor, as well
as cross-resistance to other protease inhibitors (PIs).15,16 One
of the potent, ﬁrst-generation PIs is saquinavir (SQV, Figure 1),
which acts as a peptidomimetic compound for HIV-1 PR’s
natural substrate.17 Actually, it has been characterized as a
transition-state analog of the Phe−Pro amide bond in the Gag-
Pol precursor protein (Figure 1).18 Since saquinavir was the
ﬁrst PI approved, numerous studies have provided a vast
amount of information to date regarding HIV-1 PR mutations
that reduce susceptibility to this drug. One of the issues
regarding saquinavir is the low oral bioavailability due to its
lipophilic nature.19 To overcome this, high doses of the
inhibitor are administered; however, this leads not only to
serious side eﬀects such as lipodystrophy and hypertension20
but also to increased drug resistance.
Following extensive clinical studies in patients, researchers
have isolated drug-resistant HIV-1 strains, and the correspond-
ing mutations have been identiﬁed.21 In this study, we focus on
seven important saquinavir-related, single mutations in
positions 10/10′ (L10I), 48/48′ (G48V), 63/63′ (L63P), 71/
71′ (A71V), 73/73′ (G73S), 82/82′ (V82A), and 84/84′
(I84V), as shown in Figure 1. The strength of this work lies in
the comparison of several saquinavir-associated single mutants,
something that has not been attempted to such an extent
before. Importantly, analysis on many mutants enables a broad
understanding of saquinavir resistance.21 Among these seven
diﬀerent mutation sites that have been identiﬁed, the mutation
from Gly to Val in positions 48/48′ has the greatest impact to
saquinavir resistance;22 this residue is located at the ﬂap region
of the enzyme, which is directly responsible for the entrapment
of ligands into the active site.
The clinical data on the mutations merely reveal the site of
each one, and do not provide information regarding the binding
interactions of the drug. It is of particular importance to reveal
the nature of resistance by studying on the molecular level the
changes induced to the saquinavir−protease complexes upon
diﬀerent mutations and focus on the common patterns that
may appear. Theoretical methods, such as molecular dynamics
and free energy approaches (thermodynamic integration, MM−
PBSA), oﬀer valuable insight regarding this.
Most computational studies, such as that by Ode et al.,23
consider the impact a mutation has upon drug binding, usually
in the vicinity of the mutation site. Also, most conformational
analyses24,25 look at the immediate area surrounding the drug
and assess any changes in direct drug−protein interaction
patterns,26,27 caused by the mutation. In this study, we consider
the way mutations aﬀect the entire protease structure and
compare common features among mutants, as well as between
mutants and the wild-type (wt). Conformational analysis and
the study of interactions in the mutant complexes compared to
the wt enzyme elucidate changes in the protease that may be
crucial for eﬀective binding. Here, we combine molecular
dynamics (MD), molecular mechanics Poisson−Boltzmann
surface area (MM−PBSA), and thermodynamic integration
(TI) techniques to analyze the impact of single mutations on
the binding aﬃnity of saquinavir for HIV-1 PR. The estimation
of the binding free-energy and its relative change (between wt
and mutant) oﬀers valuable information into drug−target
relationships. The potency of a new inhibitor strongly depends
on this thermodynamic potential.28,29
II. METHODS
In this section, we describe the procedures followed in our
study. First, the construction of the complexes based on the
crystal structure of the wt protease is described. The next step
involves the setup of the systems for MD simulations, and
ﬁnally we provide the speciﬁcs for the MM−PBSA and TI
analyses.
II.1. Systems. We obtained the high resolution (1.16 Å)
crystal structure of wt HIV-1 PR in complex with saquinavir
from the Brookhaven Protein Databank (PDB code: 3OXC).30
Figure 1. Representation of the saquinavir−HIV-1 PR complex (left) and the chemical structure of saquinavir (right). The positions of the seven
single mutations are highlighted in blue. A part of the Gag-Pol precursor sequence, where cleavage occurs (Phe-Pro bond) is also shown.
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For consistency in our calculations, we used this protease
structure as a template for the construction of the single mutant
complexes. We substituted the wt amino acids in positions 10/
10′, 48/48′, 63/63′, 71/71′, 73/73′, 82/82′, and 84/84′ (Table
S1), in order to create the respective single mutants. This has
been done according to previous studies examining the eﬀect of
single mutations.31−33 The active site was considered
monoprotonated in position 25, in agreement with previous
experimental and computational evidence.34,35 TI calculations
were performed for the G48V mutation, and we substituted the
Gly only in position 48 (chain A), while Gly48′ remained
unchanged. The TI method is highly sensitive to the number of
diﬀerent atoms between wt and mutated complexes; thus, for
the method to produce accurate results, the systems must not
have great changes.
II.2. Molecular Dynamics Simulations in Water. The
complexes were subjected to unrestrained MD simulations in
explicit solvent using the SANDER module of AMBER 11.36
The ﬀ99SB force ﬁeld was used to represent the behavior of the
protease.37 The parameters for saquinavir were developed with
ANTECHAMBER (using the GAFF force ﬁeld with AM1-BCC
charges).38,39 All complexes were solvated in water (using the
TIP3P water model),40 and truncated octahedral periodic
boundary conditions have been applied (cutoﬀ distance 8 Å).
Minimization of the complexes was ﬁrst performed by keeping
the solute atoms constrained (with a harmonic force constant =
500 kcal mol−1 Å−2) over 5000 steps, with the ﬁrst 2500 steps
employing the steepest descent method and the next 2500
steps with the conjugate gradient algorithm. A second 5000-
step minimization was performed with all atoms unrestrained.
Next, the systems were gently heated under constant volume
for 100 ps, with the gradual increase of the temperature from 0
to 300 K, and were equilibrated under constant pressure for
100 ps. In both heating and equilibration procedures, a restraint
of 10 kcal mol−1 Å−2 has been applied to each solute. The
constant-pressure equilibration has been prolonged for another
200 ps after all restraints had been removed. Finally, the MD
simulations (total 20 ns each) were done in the NPT ensemble,
using a Langevin dynamics temperature scaling (with collision
frequency 2 ps−1).41 All bonds involving hydrogen atoms were
constrained to their equilibrium distance (in all steps) with the
SHAKE algorithm, thus allowing for a time step of 2 fs to be
used.42 For the analysis of the hydrogen bond (HB)
interactions, the limitations were a 3.5 Å cutoﬀ for each
donor−acceptor distance and a donor−hydrogen−acceptor
angle cutoﬀ of 120°. HB, RMSD, atomic ﬂuctuations, and
clustering calculations were performed with the ptraj program
of AMBER.
II.3. Molecular Mechanics Poisson−Boltzmann Sur-
face Area Calculations. MM−PBSA expresses the binding
energy of a system (eq 1) as a sum of enthalpy (H) and entropy
(S) parts (eq 2).43 The enthalpy component is further
decomposed in various contributions (eq 3, van der Waals,
ΔEvdW; electrostatic, ΔEelec; nonpolar solvation, ΔGNP; and
polar solvation, ΔGPB). The van der Waals and electrostatic
components are calculated using molecular mechanics (MM),
while the estimation of the electrostatic contribution to the
solvation free energy is achieved with the Poisson−Boltzmann
equation. The nonpolar contribution to the solvation energy is
calculated with an empirical method based on the solvent
accessible surface area (SASA),44 as shown in eq 4.
The binding free energy of the complex, for a given snapshot,
is given by
Δ = − +G G G G( )bind complex receptor ligand (1)
where G is the free energy of each system (complex or receptor
or ligand) calculated as the average of free energies over the 20
ns trajectory.
Δ = Δ − ΔG H T Sbind (2)
Δ = Δ + Δ + Δ + ΔH E E G Gelec vdW PB NP (3)
γ βΔ = +G SASANP (4)
For the surface tension γ and the oﬀset β, the default values of
0.00542 kcal mol−1 Å−2 and 0.92 kcal mol−1 were used,
respectively. ΔGNP is computed via eq 4, with the linear
combinations of pairwise overlaps (LCPO) method.45
The HIV-1 PR binding cavity is highly hydrophobic,44 and
according to previous theoretical studies46,47 the dielectric
constants better suited to our calculations for the solvent and
the solute are 80.0 and 1.0, respectively. The entropic
component of eq 2 was calculated with normal-mode analysis.
To model the water environment around the protein, MM−
PBSA strips the explicit water molecules and uses a
parametrized implicit water model (PB). While enthalpy
calculations were performed on 2000 frames of each trajectory,
only 200 snapshots were used for the entropy estimation, to
save computational time.
II.4. Thermodynamic Integration Calculations. Calcu-
lating the binding energy (ΔG) in protein complexes oﬀers
insights into the binding mechanism. However, the most
important information when comparing complexes, such as wt
and mutant proteases (in this case only for G48V), comes from
the relative diﬀerence (ΔΔG) between the two states.48 TI is a
technique that calculates the relative energy diﬀerence from
MD or Monte Carlo (MC) simulations and is based on the
following scheme:
where
ΔΔ = Δ − Δ = Δ − ΔG G G G G2 1 4 3 (5)
ΔG1 and ΔG2 represent the binding of a ligand to two diﬀerent
proteins (wt and mutated forms), while ΔG3 and ΔG4
represent transformations from one protein to the other, either
being only solvated in water (ΔG3) or when bound to a ligand
(ΔG4).
The TI method calculates the binding free energy based on
the following equation:48
∑ λ λΔ =
∂
∂=
⎜ ⎟⎛⎝
⎞
⎠G W
V
i
n
i i
1 (6)
where λ is the coupling parameter and V denotes the λ-coupling
potential function.49 The values for λ and their respective
weights (Wi) are assigned based on the Gaussian quadratic
formula.50 For λ = 0, the V(0) potential function corresponds
to the wt, and for λ = 1, the V(1) potential function
corresponds to the single mutant G48V. The TI procedure was
realized for each λ in three steps: (a) charge removal from the
Hα atom of Gly, (b) changing Gly into Val, and (c) charge
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addition on all side chain atoms of Val. Since the wt and mutant
enzymes have diﬀerent numbers of atoms due to the change in
position 48, we used soft-core potentials51 that were activated
only during the second step, which involves the disappearance
and appearance of atoms. MD simulations for the TI
calculation were performed according to the protocol described
above. The sampling space was deﬁned by 12 diﬀerent λ values,
and for each λ we ran six (three steps for each wt and G48V)
independent, 2 ns MD simulations. For our calculations, the
values of λ and their respective weights were taken from the
AMBER 11 manual (Table S2).
III. RESULTS
The comparison of wt and mutant molecular trajectories
showed the diﬀerences and similarities among structures, as
summarized in Table 1. Despite its potency, saquinavir’s
continuous administration soon led to the emergence of drug
resistant strains. Therefore, it is imperative to understand the
behavior of the drug in the diﬀerent PR mutants that have
arisen due to its use.
III.1. Conformational Analysis of Saquinavir in the
Binding Site of wt and Mutated Forms of HIV-1 PR.
RMSD calculations for the Cα atoms of HIV-1 PR in wt and all
mutated complexes showed that the simulations converged
after ≈10 ns, thus yielding stable trajectories for all systems
(Figure S1). The calculation of the RMSD may also provide
information on the structure of the drug inside the protease: in
Figure 2, the RMSD for all atoms of the drug (compared to its
initial conformation) in wt, G48V, L63P, A71V, V82A, G73S,
I84V, and L10I are presented. The most prominent changes in
saquinavir were observed in the A71V mutant, with the RMSD
stabilizing to ≈1.8 Å by the end of the simulation. In all other
complexes, the structure of saquinavir does not present
signiﬁcant changes from the starting conformation, with values
ﬂuctuating around 1.2−1.5 Å. The only exception is presented
in the mutant strain V82A, where the inhibitor inside the active
site shows the lowest RMSD during the simulation, with a
mean value of ≈0.9 Å. This may attest that the particular
mutation does not induce major changes in saquinavir
throughout the simulation. Although the conformations of
the drug inside the binding cavity of V82A resemble its starting
structure, during the ﬁrst half of the simulation, saquinavir
appears more mobile in V82A than in any other mutant;
however, it eventually stabilizes after 10 ns. One may also note
that saquinavir in G48V is slightly more ﬂexible than when
bound to the wt.
Clustering Analysis. Following the RMSD calculations of
saquinavir inside the binding cavity of the enzyme, we
performed a clustering analysis. Calculations have been carried
out for the drug in wt and in all single mutant complexes. One
common characteristic in all systems is the presence of only
one representative conformation of the drug, as shown in
Figure S2. This strongly suggests that saquinavir inside the
Table 1. Summary of Major Findings in wt and Single Mutant Saquinavir−HIV-1 PR Complexes
complexes
average ﬂap
RMSD (Å)
RMSD between SQV in mutated forms and its
structure in wt (Å)
no. of H-
bonds
water-mediated
interactions
ΔGMM‑PBSA
(kcal/mol)
Ki
MM‑PBSA
(nM) Ki
exp (nM)
wt 0.52 7 2 −12.25 2.5 0.4222
L10I 0.99 1.67 5 2 −11.53 7.4
G48V 0.55 3.16 3 −11.10 14.5 3622
L63P 1.39 4.03 4 1 −10.89 21
A71V 1.45 3.99 4 2 −12.04 3.2
G73S 0.68 1.73 5 4 −11.82 4.6
V82A 0.87 4.21 3 −11.76 5.1
I84V 0.86 1.29 3 −10.90 20.6
Figure 2. RMSD for saquinavir with respect to its initial conformation in HIV-1 PR complexes: (a) wt (blue) and G48V (red); (b) L63P (blue),
A71V (red), V82A (green), G73S (black), I84V (purple), and L10I (yellow). The gray line shows the average RMSD for saquinavir in the wt
complex. For clarity, individual RMSD plots for each mutant are presented in Figure S5.
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binding cavity adopts an orientation that favors certain
interactions between itself and the protease.
In wt HIV-1 PR, saquinavir adopts a slightly “bent”
conformation (Figure S2) that may assist in favorable
interactions with the protein. The MD representative structure
of saquinavir resembles the crystal structure of the drug, with an
RMSD between them of only 0.41 Å. Interestingly, saquinavir
in the G73S mutant also resembles its structure in wt (Figure
S2); the RMSD between the two conformations is 1.73 Å.
Similarly, there is no large diﬀerence between saquinavir into wt
and into the I84V and L10I single mutants that present RMSD
values of 1.29 Å and 1.67 Å, respectively.
Compared to saquinavir in wt, a structural diﬀerence was
observed for its representative structure in the V82A mutant,
where the RMSD between them is 4.21 Å; the representative
conformation of saquinavir inside V82A adopts a more
extended form. Similar structures were observed for the drug
in L63P and A71V that have RMSD of 4.0 Å, compared to the
wt. This conformational change in saquinavir may have
contributed to the overall RMS change observed for the
A71V complex in Figure 2b.
Another feature arising from the clustering analysis is the
stability of the hydroisoquinoline group in saquinavir. The
group shows the smallest conformational variation in all
representative structures between wt and mutant strains. It
was suggested that this moiety is less ﬂexible than the quinoline
group in saquinavir. In conclusion, however, saquinavir presents
a stable conformation inside the active site cavity of the
protease. This is of importance regarding the binding process
and consequently the mechanism of inhibition.
III.2. Conformational Properties of the Flap Region. As
observed in other experimental and theoretical studies, ligand
binding is closely related with conformational changes on the
ﬂaps of the enzyme.12,13 This region is deﬁned by residues 44−
55 and 44′−55′, and has been implicated in the modulation of
the entrance and trapping of ligands inside the catalytic site.
Thus, following the analysis regarding the structure of the drug
in the active site, it has been deemed important to consider the
ﬂap region in the diﬀerent mutants.
In Figure 3, we have depicted the RMS deviations
throughout the simulation for the ﬂap region. It is important
to note that the only mutant belonging to the ﬂap region of the
enzyme is G48V, with Gly48 being very close to the ﬂap tip.
Therefore, any mutations in this position are likely to induce
changes in the overall structure of the protein. The analysis of
the G48V trajectory compared to the wt showed minor changes
in the ﬂap region as depicted by the RMSD values (Figure 3a).
However, it has been suggested in other studies that the change
from Gly to a more hydrophobic residue such as Val could
cause a speciﬁc structural change in the tip of the ﬂap
(Ile50).22,32 Namely, the ﬂap tip in the G48V mutant has been
shown to create a curl that subsequently aﬀects the interaction
Figure 3. RMSD for the ﬂap Cα atoms (residues 45−55 and 45′−55′), with respect to their initial conformation in HIV-1 PR complexes: (a) wt
(blue) and G48V (red); (b) L63P (blue), A71V (red), V82A (green), G73S (black), I84V (purple), and L10I (yellow). Individual plots for each
mutant are shown in Figure S6.
Figure 4. Atomic ﬂuctuations for protease residues in the HIV-1 PR complexes: (a) wt (blue) and G48V (red); (b) L63P (blue), A71V (red), V82A
(green), G73S (black), I84V (purple), and L10I (yellow). For clarity, individual plots for each mutant are shown in Figure S7.
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between ﬂaps. Such a behavior was not observed in our case,
since phi−psi plots for residues 48−51 revealed minor
diﬀerences between wt and mutated complexes (Figure S3).
The only exception was observed in Gly49 (φ angle) for the
mutated form, which showed a slight deviation from the α-helix
wt structure. Interestingly, however, Cα atomic ﬂuctuations of
the protease residues in wt and G48V (Figure 4a) showed that
the ﬂap tips in G48V are more mobile than in wt. This indicates
the absence of signiﬁcant interactions between the two ﬂaps of
HIV-1 PR in the mutated form and consequently the less
eﬀective entrapment of the inhibitor inside the binding cavity.
Following this observation, we investigated the same region
in the other single mutations. In all other mutants, the RMS
deviations for the ﬂap region were greater than the wt (Figure
3b). The only exception is G73S, which presented similar
values to the wt. The most profound changes in the ﬂaps of the
protease came from mutations L63P and A71V. Indeed in these
cases, the RMSD reached up to 2 Å compared to the starting
conformation. Furthermore, they occasionally return to lower
values, thus suggesting that they probably alternate between
“semi-open” and “closed” states several times during the
simulation. However, their respective atomic ﬂuctuations
appear to be signiﬁcantly low (Figure 4b) and comparable to
the wt. This suggests that despite their conformational changes,
the ﬂaps are primarily stable during the simulation.
Extending our analysis to other parts of the protease, we
observed that the terminal regions including residues 80−99
and 1′−20′ appear increasingly mobile in most complexes.
These residues are located at the interface between the two
monomers of the protein. Many of the single mutations studied
here are close to this area. Therefore, any changes in these
residues may aﬀect the stability of the dimer and consequently
the activity of the enzyme. Although single mutations G48V,
G73S, and L10I do not present any major conformational
changes in the ﬂap region (Figure 3b), the atomic ﬂuctuations
regarding the ﬂap tip residues (Ile50/50′) show greater
mobility compared to all the other single mutants. Also, I84V
shows similar mean RMS values with the single mutant G73S,
both for the ﬂap region and for saquinavir into the cavity
(compare Figures 2 and 3). Although the amino acids in
positions 73 and 84 are diﬀerent, it may be hypothesized that
any changes in the speciﬁc area do not lead to signiﬁcant
conformational changes in the enzyme.
III.3. Interactions Involving wt and Single Mutant
Complexes. Following the conformational analysis, we next
investigated the interactions between the protease (wt and
mutants) and saquinavir. The hydrogen bonds (HBs) between
the drug and the enzyme may provide information on the
changes caused by the mutations and the behavior of saquinavir
in diﬀerent viral strains.
HB analysis of the MD trajectories revealed that saquinavir
forms seven HB interactions with wt protease (Tables 2 and S3
and Figure 5a). The bent conformation of the drug (Figure S2)
favors the formation of HBs that involve Gly48′ at the ﬂap of
the protease, both aspartic acids in the catalytic site, and Arg8.
This extensive network of interactions serves in anchoring
saquinavir strongly into the binding cavity. The most frequent
HB with Gly48′ (being present for 81% of the simulation) is
followed by another one with Asp25 (58%); both bonds are
dispersed throughout the simulation. Also, saquinavir forms
three HBs with the catalytic Asp in position 25′. The presence
of all these interactions may rationalize the existence of only
one structural cluster for the drug in the wt (Figure S2). Finally,
Arg8 presents an HB (29%) that further strengthens the
positioning of saquinavir into the binding cavity (Table S3).
The interaction between saquinavir and Gly48′ denotes the
importance of the ﬂap region in successfully trapping the ligand
inside the protease.12,13
Our analysis revealed that saquinavir interacts also with ﬁve
water molecules. Of these interactions, two are of particular
interest (Tables 2, S3): two water molecules mediate HB
interactions between saquinavir and Asp29 at the active site of
the protease (Figure 5a). The involvement of water in direct
HBs with the ligand may play a crucial role in the binding
mechanism of the complexes.
Compared to the wt protease, the single mutant G48V
presents a much less extensive HB network with saquinavir,
with only three HBs between the inhibitor and the enzyme
(Table S3, Figure 5b). Similarly to the wt, there is a direct
interaction between the drug and amino acids on the catalytic
site of the enzyme, where saquinavir forms a double HB with
Asp25′ (occurrence 32%). However, the saquinavir−Gly48′
interaction observed in the wt complex has been replaced by an
HB between the drug and ﬂap tip Ile50′ (56%, Figure 5b). In
G48V, the mutation from Gly to the more hydrophobic Val
causes the loss (or diminishing) of certain interactions between
saquinavir and protease:52 the saquinavir−Ile50′ HB in G48V is
not as dominant compared to the saquinavir−Gly48′
interaction in wt (Table 2). This change inﬂuences the stability
of the ﬂap region and at the same time also perturbs
interactions inside the binding cavity that consequently lead
to weaker binding of the drug to the protease.31 This may
rationalize the role of G48V as a major mutation conferring
resistance to saquinavir, as well as to other PIs (e.g., ritonavir
Table 2. Principal Hydrogen Bonds in Saquinavir−HIV-1 PR Complexesa
SQV−residueb wt L10I G48V L63P A71V G73S V82A I84V
Asp25 58 33/23 88
Thr26 20 11 11
Asp25′ 45 32 19 88 100
Asp29′ 95 13 100 61
Gly48′ 81 60
Ile50′ 56
Asp25−H2O−SQV 20
Asp29−H2O−SQV 39 35 12 40
Ile50′−H2O−SQV 36
aFor detailed information regarding the HB interactions, see Table S3 in the Supporting Information. bOccupancy is given as the percentage of
simulation time that a speciﬁc interaction exists; interactions occurring less than 10% of the simulation time are not shown.
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and atazanavir).21,53 Furthermore, water-mediated interactions
between drug and enzyme are not present in the HIV-1
PRG48V complex.
HBs in all other single mutations are also diminished
compared to the wt. A prevalent feature in L63P, V82A, A71V,
and I84V single mutants is the absence of HB interactions
between saquinavir and the ﬂaps of the protease (Tables 2 and
S3). Thus, one may deduce that the drug is not anchored
strongly in the active site. The absence of interactions between
ﬂap residues and the drug may partially explain the decrease in
the binding energy of saquinavir upon mutations. It may also be
responsible for the greater structural changes of the single
mutants compared to wt (Table 1). In L63P, saquinavir
interacts only with residues at (or near) the active site (Thr26,
Asp25′, Asp30, and Arg8′). One interesting feature is that the
interaction between Asp30 and saquinavir involves the aromatic
ring of the drug (π interaction). Similar π interactions were also
present in the mutants L63P and A71V (Table S3).
As mentioned in other studies,54 water molecules aﬀect
ligand binding and also participate directly in the cleavage
Figure 5. Main hydrogen bonds for saquinavir in complex with (a) HIV-1wt PR and (b) HIV-1G48V PR. Red dotted lines denote interactions with
catalytic aspartic acids at positions 25 and 25′. The side chains of amino acids participating in HBs are shown.
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mechanism of the protease.35,55 Thus, we investigated possible
protease−water−saquinavir interactions in all complexes, to
ﬁnd that they are present only in the L10I, L63P, A71V, and
G73S strains. An interesting characteristic is that most water
mediated HBs occur in the region of the active site (Asp25/
29). Contrary to the other mutated complexes, in V82A,
saquinavir forms two HBs with aspartic acids at positions 25′
and 29′ that are present throughout the simulation and hold
saquinavir strongly attached at the active site of the protease
(Table 2). This ﬁnding supports previous studies, which
suggested that the V82A mutation is not conferring any major
resistance to saquinavir.33
Interactions involving residues near or at the active site are
present in all single mutants. Another common feature in wt
and mutated forms is the HBs between saquinavir and Asp25/
25′ and Thr26/26′ in L10I, A71V, and G73S. Also, in G73S the
interaction between the drug and Gly48′ is also prevalent. In
A71V, although there is no direct interaction between the ﬂap
residues and the drug, there is a water mediated interaction
between Ile50′ and saquinavir. This highlights the importance
of the active site residues and the ﬂaps in anchoring the drug in
opposite sides of the binding cavity, with direct implications
toward eﬀective saquinavir binding.
III.4. Intraﬂap and Interﬂap Interactions. The analysis of
the HB interactions between saquinavir and the protease
revealed the importance of the ﬂaps in the ligand binding
process. Therefore, we considered it extremely important to
focus our interest in the ﬂap region.48
As mentioned above,21 G48V has been implicated as a major
mutation conferring resistance to saquinavir. In Tables 3 and
S4, we present the HB interactions involving the ﬂaps of wt and
the G48V mutant: it is evident that the ﬂaps of the protein are
stabilized in both complexes via signiﬁcant interﬂap and
intraﬂap interactions; however, interﬂap HBs are signiﬁcantly
more dominant in the wt.
Of major importance was the presence of a water molecule
between the ﬂap tips (Ile50 and Ile50′) of the enzyme in the
saquinavir−wt complex (Table 3). This is in accordance with
other studies56−58 that have explored the role of water in
diﬀerent HIV-1 PR systems. The mutation in position 48 from
Gly to Val causes a weakening of the interactions between the
two ﬂaps of the protease. In the wt complex, the Ile50−Ile50′
HB has an occurrence of 76%, while in the G48V mutant this
interaction is absent. This indicates that the particular mutation
causes conformational changes in the vicinity of the ﬂaps, as
being hypothesized above. The more hydrophobic chain of Val
compared to Gly leads to structural changes in the neighboring
amino acids, which in turn may aﬀect the binding of saquinavir.
This observation is further supported by structural studies on
the double mutant strain G48V/L90 M that show the eﬀect of
the ﬂap mutation in the conformation of the ﬂap region.52 The
crystal structure of the double mutant has provided information
on the importance of Gly48: it has been suggested that the
change from Gly to Val leads to a signiﬁcant loss of interactions
between saquinavir and the protease.53 Similarly, we observed
that mutation G48V has greatly impacted the interﬂap
interaction potential by abolishing interactions between Ile50′
and Ile50, as well as between Ile50′ and Gly52 (Table 3). Also,
saquinavir in the G48V interacts less eﬀectively (compared to
the wt) with the ﬂap via an HB with Ile50′ (56%, Table 2). This
may have induced changes in interﬂap interactions leading to
the replacement of the Ile50′−Ile50 HB (present in wt) with a
less frequent interaction between Ile50 and Gly51′ (42%).
Compared with the previous changes conferred by the G48V
mutation in the ﬂaps, it is not surprising that viral strains with
the particular mutation show increased resistance to saquinavir.
The relation of Gly48 to the ﬂap stability is also depicted by
the atomic ﬂuctuations of the ﬂap residues in Figure 4. The
conformational changes caused by the mutation, together with
the interactions that form or disappear in the two complexes,
greatly increase the mobility of the ﬂap region in G48V mutant.
Table 3. Flap−Flap HB Interactions in wt and G48V
Saquinavir Complexes
occupancy (%)
residue 1 residue 2 wt G48V
Ile50′ Ile50 76
Ile50′ Gly52 26
Ile50 Gly51′ 42
Ile50−water−Ile50′ 25
Table 4. Energetic analysis for saquinavir−HIV1-PR complexes as obtained by MM−PBSA and TI calculations
saquinavir−HIV-1 PR
energya (kcal/mol) wt L10I G48V L63P A71V G73S V82A I84V
ΔEelec −48.35 −47.45 −45.54 −45.18 −47.51 −46.53 −43.80 −45.04
ΔEvdw −52.18 −51.89 −55.22 −49.47 −50.67 −52.74 −54.23 −55.69
ΔEMM −100.53 −99.34 −100.76 −94.65 −98.18 −99.27 −98.03 −100.73
ΔGNP −9.35 −9.80 −10.01 −9.65 −8.74 −10.12 −9.04 −9.77
ΔGele 74.29 72.97 75.18 71.27 71.47 74.87 70.51 74.24
ΔGsolv 64.94 63.17 65.17 61.62 62.73 64.75 61.46 64.47
ΔH(MM+solv) −35.59 −36.17 −35.59 −33.03 −35.45 −34.52 −36.63 −36.26
−TΔStot 23.34 24.64 24.49 22.14 23.41 22.70 24.87 25.36
ΔGbindMM‑PBSA −12.25 −11.53 −11.10 −10.89 −12.04 −11.82 −11.76 −10.90
Ki (nM)
b 2.5 7.4 14.5 21 3.2 4.6 5.1 20.6
ΔΔGTI 0.28
ΔΔGMMPBSA 0.72 1.15 1.36 0.21 0.43 0.49 1.35
ΔΔGexp 2.65
Kiexp(nM) 0.42
c 36c
aThe standard deviation values for the energy calculations are presented in Table S4. bThe Ki values were calculated based on the equation ΔG = RT
ln Ki.
cSee ref 22.
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III.5. Energetic Analysis. The MM−PBSA results revealed
the impact of mutations on the binding aﬃnity of saquinavir to
HIV-1 PR (Table 4). Enthalpy and entropy plots over time for
all HIV-1 PR complexes showed that the binding energy
calculations converged after approximately 10 ns (Figure S4).
Our calculations supported G48V being a major mutation, as
it has a noticeable impact compared to the wt (ΔΔGMM−PBSA =
1.15 kcal/mol). Similarly, the MM−PBSA calculations showed
that single mutations I84V and L63P reduce the binding aﬃnity
signiﬁcantly, by approximately 1.35 kcal/mol. Both mutations
involve changes from long side chains (Ile and Leu) to shorter
(Val) or more rigid (Pro) amino acids. Ile84 is positioned
inside the binding cavity, and we notice that a change to an
amino acid with a shorter side chain (Val) may lead to the loss
of several HB interactions (Table 2). By decreasing the
potential for HB formation inside the binding cavity, the
inhibitor may not be eﬀectively bound. On the other hand, the
L63P mutation did not aﬀect the binding of the ligand directly,
since this amino acid is located away from the binding cleft. It is
part of a β-sheet conformation that supports the ﬂaps of the
enzyme (Figure 1). Changes in this position may destabilize the
conformation of the ﬂaps and indirectly reduce ligand binding.
The lowest impact was observed in the single mutant A71V,
with a binding energy of −12.04 kcal/mol (ΔΔGMM−PBSA =
0.21 kcal/mol). This could be partially attributed to the close
structural relationship between Ala and Val, since they have
similar size and both are hydrophobic; their similar nature may
have resulted in the preservation of HBs in A71V and in the
presence of water bridges, as shown in Table 2. Thus, it may be
hypothesized that this mutation does not readily aﬀect the
binding of the drug.
Single mutants L10I and V82A belong to the binding cavity
and alter directly the interactions of the drug with the protease.
This can be explained by ﬁrst considering the extensive HB
network in wt HIV-1 PR: the presence of HBs on two opposite
sides of the cavityGly48′ (ﬂap) and Asp25 (active site)
may readily justify the high inhibitory eﬀect of saquinavir.
However, this trend is not observed to a signiﬁcant extent in
any of these single mutants. Thus, it could partially rationalize
the decrease in the binding aﬃnity of saquinavir.
Mutations (e.g., V82A, I84V) that are close to the interface of
the two monomers of HIV-1 PR (two α-helices that support
the binding cleft residues 84−94/84′−94′)16 aﬀect the
interactions between them and consequently lead to decreased
functionality of the enzyme. However, the two permanent
HBswith Asp25′ and Asp29′in V82A may justify that the
calculated binding aﬃnities (Ki) between wt and V82A show
very small diﬀerences (2.5 nM and 5.1 nM, respectively). This
is not surprising, since only in patients that have undergone
prolonged treatment with saquinavir did the V82A mutation
confer resistance, and usually in conjunction with the mutation
G48V.21,54 However, mutation V82A is important in
developing resistance to other drugs, such as indinavir and
ritonavir.59
The MM−PBSA analysis also oﬀers individual contributions
to the binding energy (Table 4). A general feature is that they
are fairly similar in all mutations with the van der Waals
interactions being the most prominent, closely followed by the
electrostatic contributions to the total binding energy. Also, the
nonpolar contribution to solvation is a signiﬁcant component,
mostly in G48V and G73S complexes.
The impact of a mutation to the binding aﬃnity of saquinavir
can be further elucidated by calculating the enthalpy (ΔH)
contributions of individual amino acids. A comparison between
the wt protease and the G48V mutant is presented in Figure 6.
The graph shows the energy contributions of important
residues (active site and ﬂaps). In the wt, all selected amino
acids had favorable contributions ranging from −0.1 to −2.2
kcal/mol, whereas in the G48V mutant, residues at the active
site (Asp25′ and Gly27/27′) and the ﬂaps (Val48/48′ and
Gly51/51′) show unfavorable contributions. Interestingly, the
greatest loss in binding enthalpy is due to mutated ﬂap residues
48 and 48′. It is worth mentioning that although active site
residues, such as Thr26/26′ and Gly27/27′, did not participate
in HBs with saquinavir, they favored inhibitor’s binding into wt,
while they displayed a minor or negative contribution to the
binding energy in the mutated complex. Despite the
preservation of the HB between Asp25′ and saquinavir in the
G48V mutant, the contribution to the binding energy for the
speciﬁc residue is still unfavorable. This suggests that the
mutation causes structural rearrangements to the binding cavity
leading to a decreased binding aﬃnity.
Besides enthalpy, the changes observed in the conforma-
tional entropy of a complex greatly aﬀect the binding aﬃnity,
and failure to take them into account may lead to over-
estimations in the energy proﬁle of the system.60 It has been
shown that in certain PIs, such as saquinavir, the entropic
component has a great impact on their binding.31 Our
calculations (Table 4) show similar patterns regarding the
total conformational entropy with previous studies.23,60 In
G48V, the contribution of enthalpy was not aﬀected by the
mutation (ΔHwt = ΔHG48V); upon G48V mutation, the
favorable van der Waals change (ΔEvdW,G48V = −55.22 kcal/
mol, ΔEvdW,wt = −52.18 kcal/mol) was balanced with the
unfavorable change in electrostatic interactions (ΔEelec,G48V =
−45.54 kcal/mol, ΔEelec,wt = −48.35 kcal/mol) to maintain ΔH
practically ﬁxed. Thus, the loss in binding energy for G48V is
solely attributed to the change in entropy. Furthermore, it was
observed that the vibrational entropy for G48V versus the wt is
unfavorable by ≈1 kcal/mol (−TΔSvib,G48V = 3.87 kcal/mol and
−TΔSvib,wt = 2.98 kcal/mol, Table S6), in accordance with
previous observations.31
To reach a higher level of accuracy, the TI method has been
employed for the calculation of the relative free energy of
binding, between the wt and G48V complexes. Negative (or
positive) values of ΔΔGTI denote whether the mutation is a
Figure 6. Per residue contributions to ΔH for saquinavir complexes
HIV-1wt PR (green) and HIV-1G48V PR (blue). Individual contribu-
tions for active site and ﬂap residues are displayed.
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favorable (or unfavorable) process. In this case, the estimated
value for ΔΔGTI is 0.28 kcal/mol. This shows that the amino
acid change from Gly to Val negatively impacted saquinavir’s
binding aﬃnity. This, in combination with the results obtained
from the conformational and MM−PBSA analyses further
strengthens the importance of the ﬂap region in successfully
trapping saquinavir inside the binding cavity. In agreement with
previous experimental evidence, the value of the free energy
change between the two states was calculated to be slightly
positive, as a single mutation is expected to confer low level
resistance.15,16,22
IV. CONCLUSIONS
The conformational properties and binding modes of eight
saquinavir−HIV-1 PR complexes in the wild-type and single
mutant forms, L10I, G48V, L63P, A71V, G73S, V82A, and
I84V, have been investigated by means of MD simulations and
binding free-energy (MM−PBSA and TI) calculations. Binding
energy analysis showed that mutations G48V, L63P, and I84V
signiﬁcantly deteriorate saquinavir binding compared to the
wild-type and other mutated complexes. In contrast, A71V had
a negligible eﬀect on the binding aﬃnity of saquinavir. An
extensive comparison of structural properties, energetics, and
dynamics for all systems indicated the main reasons that
particular mutations confer resistance to saquinavir: (1)
Mutations that induce ﬂexibility to the ﬂaps of the protease
(G48V, L63P, L10I, G73S) lead to the reduction of binding.
Conversions of the ﬂaps between semiopen and closed states
may be observed (A71V) without signiﬁcant loss in binding
aﬃnity, as long as the ﬂaps remain primarily stable. (2)
Conformational changes of saquinavir may not aﬀect binding
(V82A, A71V), provided that its structure eventually stabilizes,
as observed in the wt. The hydroisoquinoline group of
saquinavir appeared particularly stable in all systems; saquinavir
structures in all mutants adopted speciﬁc conformations that
favor certain interactions: (3) Saquinavir-related HB inter-
actions with the active site (Asp25/25′/29/29′/30/30′) and
the ﬂaps of HIV-1 PR should be present to hold the drug into
the binding cavity in a compact conformation. Mutations that
result in major resistance (G48V, L63P, I84V) do not preserve
favorable interactions with the active site and the ﬂaps. (4) A
water-mediated HB interaction between saquinavir and the
region of the active site (Asp29) is of major importance (wild-
type, A71V, G73S, L63P, L10I). Mutants that lack this
interaction (e.g., G48V, I84V) showed signiﬁcantly lower
(experimental and theoretical) binding aﬃnities. (5) Enhanced
van der Waals interactions and electrostatics are the main
contributions to the binding energy, with similar values among
mutants (−55.7 kcal/mol < ΔEvdW < −49.5 kcal/mol, −48.4
kcal/mol < ΔEelec.< −43.8 kcal/mol). This work constitutes a
computational prediction of HIV-1 PR drug resistance.
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